Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

A Randomized, Double-blinded, Placebo-controlled, Phase IIb Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

This is a multiple-center, randomized, double-blind, placebo-controlled Phase IIb study to evaluate the efficacy and safety of AK101, an anti-IL-12/23 p40 antibody, when administered subcutaneously, in subjects with moderate-to-severe plaque psoriasis. The study will consist of 3 periods: up to 4 weeks screening, 12 weeks double-blinded treatment and long-term follow-up period(up to 52 weeks).

Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

Recruitment

Summary

Participation Requirements

Description

Tracking Information